Yu-Xi Yan
Overview
Explore the profile of Yu-Xi Yan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
129
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang Y, Liu Y, Qiao W, Jin W, Zhu S, Yan Y, et al.
Acta Pharmacol Sin
. 2024 May;
45(9):1926-1936.
PMID: 38744938
Primary Sjögren's syndrome (pSS) is a chronic inflammatory autoimmune disease with an unclear pathogenesis, and there is currently no approved drug for the treatment of this disease. Iguratimod, as a...
2.
Shao M, Yan Y, Qi Q, Tang W, Zuo J
Zhongguo Zhong Yao Za Zhi
. 2019 Apr;
44(3):415-421.
PMID: 30989902
Inflammatory bowel disease(IBD) is a non-specific and chronic recurrent autoimmune disease that involves the gastrointestinal tract. Clinical symptoms of intestinal bleeding, diarrhea, and weight loss threat to human health and...
3.
Yan Y, Shao M, Qi Q, Xu Y, Yang X, Zhu F, et al.
Acta Pharmacol Sin
. 2018 Jun;
39(10):1633-1644.
PMID: 29849131
Ulcerative colitis (UC) is a chronic, nonspecific inflammatory bowel disease (IBD) characterized by complicated and relapsing inflammation in the gastrointestinal tract. SM934 is a water-soluble artemisinin analogue that shows anti-inflammatory...
4.
Lin Z, Ma M, Li H, Qi Q, Liu Y, Yan Y, et al.
Pharmacol Res
. 2017 Nov;
129:443-452.
PMID: 29155016
DZ2002, a reversible S-adenosyl-l-homocysteine hydrolase (SAHH) inhibitor with immunosuppressive properties and potent therapeutic activity against various autoimmune diseases in mice. The present study was designed to characterize the potential therapeutic...
5.
Qi Q, Li H, Lin Z, Yang X, Zhu F, Liu Y, et al.
Acta Pharmacol Sin
. 2017 Sep;
39(1):107-116.
PMID: 28880016
(5R)-5-hydroxytriptolide (LLDT-8) is a novel triptolide analog that has been identified as a promising candidate for treating autoimmune diseases and has been shown to be effective in treating murine collagen-induced...
6.
Zhang L, Li H, Wu Y, Cheng L, Yan Y, Yang X, et al.
Am J Physiol Renal Physiol
. 2017 Jan;
312(4):F769-F777.
PMID: 28100505
(5R)-5-hydroxytriptolide (LLDT-8), a triptolide derivative with low toxicity, was previously reported to have strong immunosuppressive effects both in vitro and in vivo, but it remains unknown whether LLDT-8 has a...